BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30855441)

  • 1. BIM deletion polymorphism predicts poor response to EGFR-TKIs in nonsmall cell lung cancer: An updated meta-analysis.
    Su W; Zhang X; Cai X; Peng M; Wang F; Wang Y
    Medicine (Baltimore); 2019 Mar; 98(10):e14568. PubMed ID: 30855441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Value of BIM Deletion in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs: A Meta-Analysis.
    Lv F; Sun L; Yang Q; Pan Z; Zhang Y
    Biomed Res Int; 2021; 2021():3621828. PubMed ID: 34722761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
    Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
    Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between BIM deletion polymorphism and clinical outcome of EGFR-mutated NSCLC patient with EGFR-TKI therapy: A meta-analysis.
    Ma JY; Yan HJ; Gu W
    J Cancer Res Ther; 2015; 11(2):397-402. PubMed ID: 26148607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.
    Nie W; Tao X; Wei H; Chen WS; Li B
    Oncotarget; 2015 Sep; 6(28):25696-700. PubMed ID: 26325082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
    Cardona AF; Ordóñez-Reyes C; Ruiz-Patiño A; Garcia-Robledo JE; Barron LZ; Recondo G; Rojas L; Corrales L; Martín C; Barrón F; Sotelo C; Rodríguez J; Ricaurte L; Rolfo C; Ávila J; Mayorga D; Archila P; Otero J; Mas L; Bermudez M; Gamez T; Carranza H; Vargas C; Rosell R; Arrieta O
    JCO Precis Oncol; 2021 Nov; 5():839-848. PubMed ID: 34994616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer.
    Zhao M; Zhang Y; Cai W; Li J; Zhou F; Cheng N; Ren R; Zhao C; Li X; Ren S; Zhou C; Hirsch FR
    Cancer; 2014 Aug; 120(15):2299-307. PubMed ID: 24737648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
    Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
    J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.
    Huang WF; Liu AH; Zhao HJ; Dong HM; Liu LY; Cai SX
    Medicine (Baltimore); 2015 Aug; 94(33):e1263. PubMed ID: 26287412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
    Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis.
    Huang L; Huang H; Zhou XP; Liu JF; Li CR; Fang M; Wu JR
    Medicine (Baltimore); 2019 Oct; 98(43):e17705. PubMed ID: 31651902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
    Soh SX; Siddiqui FJ; Allen JC; Kim GW; Lee JC; Yatabe Y; Soda M; Mano H; Soo RA; Chin TM; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee JH; Yang JC; Zhao M; Zhou C; Lee JK; Lee SH; Lee JY; Ahn MJ; Tan TJ; Tan DS; Tan EH; Ong ST; Lim WT
    Oncotarget; 2017 Jun; 8(25):41474-41486. PubMed ID: 28467813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
    Lee JY; Ku BM; Lim SH; Lee MY; Kim H; Kim M; Kim S; Jung HA; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2015 Jun; 10(6):903-9. PubMed ID: 26001141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
    Ariyasu R; Yanagitani N; Tadokoro K; Yamaguchi T; Uchibori K; Kitazono S; Fujita N; Katayama R; Nishio M
    Cancer Chemother Pharmacol; 2020 Oct; 86(4):517-525. PubMed ID: 32948919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory cohort study and meta-analysis of
    Sun S; Yu H; Wang H; Zhao X; Zhao X; Wu X; Qiao J; Chang J; Wang J
    Onco Targets Ther; 2017; 10():1955-1967. PubMed ID: 28435285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
    An N; Zhang Y; Niu H; Li Z; Cai J; Zhao Q; Li Q
    Medicine (Baltimore); 2016 Dec; 95(50):e5601. PubMed ID: 27977598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A meta-analysis of the comparing of the first-generation and next-generation TKIs in the treatment of NSCLC.
    Li YX; Yang JY; Xu YF; Zhang M; Zhang XP; Chen WY; Lv XD
    Math Biosci Eng; 2019 Jun; 16(5):5687-5696. PubMed ID: 31499732
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.
    Ying HQ; Chen J; He BS; Pan YQ; Wang F; Deng QW; Sun HL; Liu X; Wang SK
    Sci Rep; 2015 Jun; 5():11348. PubMed ID: 26076815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.